论文部分内容阅读
对30例皮质动脉区脑梗塞（CACI）、32例穿通动脉区脑梗塞（PACI）患者及30名年龄性别与CACI患者匹配的对照者测定血脂蛋白（a）［Lp（a）］及纤溶系统活性指标。结果：CACI患者Lp（a）水平显著高于对照者［分别为（411．21±230．42）、（204．09±171．45）mg／L，P＜0．01］，而PACI患者LP（a）水平为（301．15±198．84）mg／L，介于两者间；且两类型脑梗塞患者纤溶系统活性均显著低于对照者（均为P＜0．01）。相关分析结果表明Lp（a）可能通过对组织型纤溶酶原激活物负性影响及（或）纤溶酶原激活物抑制物正性影响而干扰纤溶系统活性。高水平Lp（a）是动脉粥样硬化性脑梗塞的危险因素。
Serum lipoprotein (a) [Lp (a)] and fibrinolysis were measured in 30 CACI patients, 32 PACI patients, and 30 age-matched sex matched CACI patients. System activity index. Results: The Lp (a) level in CACI patients was significantly higher than that in controls [(411.21 ± 230.42) and (204.09 ± 171.45) mg / L, respectively, P <0.01] The level of LP (a) was (301.15 ± 198.84) mg / L, which was between the two groups. The activity of fibrinolytic system in patients with both types of cerebral infarction was significantly lower than that in controls (all P <0.01) . Correlation analysis showed that Lp (a) might interfere with the activity of fibrinolytic system through the negative influence on tissue plasminogen activator and / or the positive effect of plasminogen activator inhibitor. High levels of Lp (a) are risk factors for atherosclerotic cerebral infarction.